Kadcyla, which treats breast cancer, can cause side effects like stomach pain or blurred vision. Learn about side effects and how to manage them.

NICE first rejected Kadcyla back in 2014, saying its cost of around £91,000 per patient at full price was too high, and that a small discount was not enough for it to be considered cost effective.

Kadcyla is approved in 113 countries and is the standard of care for people with HER2-positive eBC with residual invasive disease following neoadjuvant treatment, based on previous positive ...

Kadcyla is currently approved by the FDA for the treatment of patients with HER2-positive, metastatic breast cancer previously treated with a taxane and Herceptin. The approval was based on the phase ...

Genentech’s Kadcyla Cut the Risk of Disease Recurring by Half Compared to Herceptin in People With HER2-Positive Early Breast Cancer With Residual Disease After Neoadjuvant Treatment – At ...

KATHERINE researchers found that among patients with HER2-positive early breast cancer, at a median follow-up of 8.4 years Kadcyla showed sustained improvement in invasive disease-free survival over ...

FDA approved Roche%27s Kadcyla Drug is double-shot of medication New treatment OK%27d for patients with certain form of cancer WASHINGTON (AP) — The U.S. Food and Drug Administration has ...

Basel, 06 May 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has approved Kadcyla® (trastuzumab emtansine) for adjuvant (after surgery ...

Kadcyla, a HER2-targeted antibody and microtubule inhibitor conjugate, is also currently approved to treat patients with HER2-positive, metastatic breast cancer who previously received trastuzumab ...

Kadcyla was one of the most expensive drugs on the CDF, costing up to £65,000 per patients, and charity Breast Cancer Now took the unusual step of calling on Roche to lower its price.

Genentech, a member of the Roche Group, announced today positive long-term follow-up data from the pivotal, Phase III KATHERINE study in people with HER2-positive early-stage breast cancer who ...

At three years, 88.3% of people treated with Kadcyla in the adjuvant HER2-positive early breast cancer setting did not have their breast cancer return compared to 77.0% treated with Herceptin, an ...